Ginkgo Bioworks Holdings (DNABW) Other Non-Current Assets (2020 - 2026)
Ginkgo Bioworks Holdings (DNABW) reported Other Non-Current Assets of $3.2 million for Q1 2026, down 93.14% on a YoY basis from $46.8 million in Q1 2025, and down 93.19% quarter-over-quarter from $47.2 million in Q4 2025.
Ginkgo Bioworks Holdings (DNABW) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported Other Non-Current Assets for 7 years, with the latest figure at $3.2 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 93.14% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (down 93.14% YoY), and the FY2025 full-year result was $47.2 million, down 14.76% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $3.2 million, down from $47.2 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $97.9 million in Q2 2023, with the low at $3.2 million in Q1 2026.
- Historically, Other Non-Current Assets has averaged $59.5 million across 5 years, with a median of $55.3 million in 2024.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets soared 120.87% — and 2026, when it tumbled 93.14%.
- Ginkgo Bioworks Holdings' Other Non-Current Assets stood at $88.7 million in 2022, then sank by 34.57% to $58.1 million in 2023, then retreated by 4.68% to $55.3 million in 2024, then decreased by 14.76% to $47.2 million in 2025, then slumped by 93.19% to $3.2 million in 2026.
- The last three Other Non-Current Assets figures came in at $3.2 million (Q1 2026), $47.2 million (Q4 2025), and $46.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | - | - | 16.38 Mn | 3.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.21 Mn |
| Dec 31, 2025 | 47.17 Mn |
| Sep 30, 2025 | 46.59 Mn |
| Jun 30, 2025 | 47.02 Mn |
| Mar 31, 2025 | 46.78 Mn |
| Dec 31, 2024 | 55.34 Mn |
| Sep 30, 2024 | 59.79 Mn |
| Jun 30, 2024 | 60.21 Mn |
| Mar 31, 2024 | 60.63 Mn |
| Dec 31, 2023 | 58.06 Mn |
| Sep 30, 2023 | 97.02 Mn |
| Jun 30, 2023 | 97.95 Mn |
| Mar 31, 2023 | 97.26 Mn |
| Dec 31, 2022 | 88.73 Mn |
| Sep 30, 2022 | 43.93 Mn |
| Jun 30, 2022 | 53.02 Mn |
| Mar 31, 2022 | 49.62 Mn |
| Dec 31, 2021 | 43.99 Mn |
| Sep 30, 2021 | 26.80 Mn |
| Dec 31, 2020 | 5.60 Mn |